| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 302.33 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Purpose: Sickle cell disease (SCD) is one of the most prevalent genetic disorders, affecting around 20 to 25 million individuals throughout the world. In Sub-Saharan Africa, where it is more prevalent, it can contribute to up to 80% of under-5 mortality. Clinical manifestations of SCD are very heterogeneous and the intestinal microbiome has recently been reported to be crucial in the modulation of inflammation, cell adhesion, and induction of aged neutrophils, which are key interveners of recurrent vaso-occlusive crises. Since gut bacteria can regulate aged neutrophils, defects in either the integrity of the intestinal walls or a chronic disequilibrium of the microbiota are very likely to emerge in SCD patients. Moreover, it has been suggested that Hydroxyurea (HU), the most common treatment for SCD, shows a multimodal action and may reduce microbiome dysbiosis and aged neutrophils. In this context, we aimed to understand how SCD and HU treatment modulates the microbiome and if these changes could be related to disease severity.
Description
FCT/Aga Khan (project no. 330842553).
FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.
FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.
Keywords
Sickle cell disease Hydroxyurea Children Angola FCT_Aga Khan (project no. 330842553) FCT_UIDB/05608/2020 FCT_UIDP/05608/2020
Citation
Delgadinho M, Ginete C, Fernandes C, Santos B, Vasconcelos J, Brito M. The effect of hydroxyurea in the gut microbiome of Angolan children with sickle cell disease. In: 4th Global Congress on Sickle Cell Disease [hybrid congress], Paris (France), June 16-18, 2022. PI-03. HemaSphere. 2022;6(Aug):10.